Left ventricular device implantation for advanced cardiac amyloidosis

Paul L. Swiecicki, Brooks S. Edwards, Sudhir S. Kushwaha, Angela Dispenzieri, Soon J. Park, Morie A. Gertz

Research output: Contribution to journalArticlepeer-review

48 Scopus citations


The purpose of this study was to analyze the post-hospital outcomes in patients with senile or familial cardiac amyloidosis treated with left ventricular assist device (LVAD) implantation. From December 1, 2008 to May 31, 2012, a total of 9 patients underwent LVAD placement for heart failure secondary to amyloidosis. Prior to LVAD placement, all patients were New York Heart Association (NYHA) Class IV and had a significantly decreased cardiac index (mean 1.93 liters/min/m2 [1.64 to 2.36]). All patients tolerated LVAD implantation well. Post-operatively, 2 patients died prior to hospital discharge. Three patients died since discharge with a median survival of 13.7 months. Four patients remained alive with a follow-up of 16-24 months. The most common adverse event since placement has been gastrointestinal bleeding (3 of 9 patients). Firm conclusions cannot be drawn from our investigation, but the present observations suggest LVAD implantation is technically feasible for patients with severe heart failure due to advanced cardiac amyloidosis.

Original languageEnglish (US)
Pages (from-to)563-568
Number of pages6
JournalJournal of Heart and Lung Transplantation
Issue number5
StatePublished - May 1 2013


  • cardiac amyloidosis;
  • familial amyloidosis
  • left ventricular assist device;
  • light chain amyloidosis;
  • restrictive cardiomyopathy;
  • senile amyloidosis;

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine
  • Transplantation


Dive into the research topics of 'Left ventricular device implantation for advanced cardiac amyloidosis'. Together they form a unique fingerprint.

Cite this